Myocyte enhancer factor 2: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (15 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='1tqe' size='350' side='right' caption='Mouse HDAC9 (aquamarine) complex with myocyte-specific enhancer factor (green) and DNA (PDB entry [[1tqa]])' scene=''> | |||
==Understanding of the Recruitment of HDACs by MEF2, Based on Their Structure== | |||
A biological field that has recently gained status is the so called Epigenetics. This term refers to changes in phenotype (appearance) or gene expression caused by mechanisms other than changes in the underlying DNA sequence. Among many factors that act as epigenetic regulators, we can find some proteins that deal with histone ornamentation, such as the antagonists histone acetyltranferases (HATs)[http://en.wikipedia.org/wiki/Histone_acetyltransferase] and the '''histone deacetylases''' (HDACs)[http://en.wikipedia.org/wiki/HDAC]. These proteins act respectively inserting/removing acetyl groups to lysine residues that are contained in histone proteins, making chromatin structures tighter/looser and as a result, promote/repress gene expression<ref>PMID:9798649</ref>. | |||
=Understanding of the Recruitment of HDACs by MEF2, Based on Their Structure= | |||
A biological field that has recently gained status is the so called Epigenetics. This term refers to changes in phenotype (appearance) or gene expression caused by mechanisms other than changes in the underlying DNA sequence. Among many factors that act as epigenetic regulators, we can find some proteins that deal with histone ornamentation, such as the antagonists histone acetyltranferases (HATs)[http://en.wikipedia.org/wiki/Histone_acetyltransferase] and the histone deacetylases (HDACs)[http://en.wikipedia.org/wiki/HDAC]. These proteins act | |||
Among the subgroups of HDACs, we can cite the class IIa HDACs. Such proteins shuttle from nucleus to cytoplasm in a Ca++ dependent fashion and need to associate to other transcriptional factors, such as MEF2, to have their nuclear activity, because they are unable to anchor to the chromosomes by themselves. | Among the subgroups of HDACs, we can cite the class IIa HDACs. Such proteins shuttle from nucleus to cytoplasm in a Ca++ dependent fashion and need to associate to other transcriptional factors, such as MEF2, to have their nuclear activity, because they are unable to anchor to the chromosomes by themselves. | ||
| Line 15: | Line 13: | ||
Additionally, by looking to the <scene name='Sandbox_Reserved_1/False_dimer/2'>structure</scene> obtained by X-ray crystallography, one could also think that complexes HDAC9/MEF2/DNA dimerize ''in vivo''. During the crystallization process, two complexes were contained in the same asymmetric unit, giving such a false impression. Thus, it is important to emphasize that the biological unit would be composed only by <scene name='Sandbox_Reserved_1/Complex/5'>a monomer of HDAC9, a dimer of MEF2 and a fragment of double strand DNA</scene>[http://www.ebi.ac.uk/pdbe/pqs/pqs-bin/macmol.pl?filename=1TQE]. | Additionally, by looking to the <scene name='Sandbox_Reserved_1/False_dimer/2'>structure</scene> obtained by X-ray crystallography, one could also think that complexes HDAC9/MEF2/DNA dimerize ''in vivo''. During the crystallization process, two complexes were contained in the same asymmetric unit, giving such a false impression. Thus, it is important to emphasize that the biological unit would be composed only by <scene name='Sandbox_Reserved_1/Complex/5'>a monomer of HDAC9, a dimer of MEF2 and a fragment of double strand DNA</scene>[http://www.ebi.ac.uk/pdbe/pqs/pqs-bin/macmol.pl?filename=1TQE]. | ||
*'''MEF2A''' is a substrate for p38<ref>PMID:9858528</ref>. | |||
*'''MEF2B''' and '''MEF2D''' are potent trans-activators expressed in early myogenic lineages<ref>PMID:8669199</ref>. | |||
*'''MEF2C''' controls chondrocyte hypertrophy and bone development<ref>PMID:17336904</ref>. | |||
== Disease == | |||
High expression of MEF2C is observed in leukemia<ref>PMID:23435431</ref>. Mutations in MEF2A are associated with coronary artery disease and myocardial infraction<ref>PMID:20031581</ref>. Mutations in MEF2B are associated with non-hodgkin lymphoma<ref>PMID:26245647</ref>. | |||
==Additional Resources== | |||
For Additional information, See [[Transcription and RNA Processing]] | |||
</StructureSection> | |||
== 3D Structures of myocyte enhancer factor 2 == | |||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | |||
[[1egw]], [[1c7u]], [[3kov]] – hMEF2A N terminal + DNA – human<br /> | |||
[[3mu6]] – hMEF2A N terminal (mutant) + DNA <br /> | |||
[[3p57]] – hMEF2A N terminal + DNA + histone acetyltransferase<br /> | |||
[[6c9l]] – hMEF2B <br /> | |||
[[1n6j]] – hMEF2B N terminal + DNA + calcineurin-binding protein<br /> | |||
[[1tqe]] – hMEF2B N terminal + DNA + histone deacylase 9 peptide<br /> | |||
[[6wc5]] – hMEF2B + NKX-2.5 + DNA<br /> | |||
[[7x1n]] – hMEF2D + DNA<br /> | |||
[[5f28]] – MEF2C N terminal + focal adhesion kinase 1 - mouse<br /> | |||
== References == | |||
<references/> | |||
[[Category:Topic Page]] | |||
Latest revision as of 06:54, 10 July 2023
| ||||||||||||
3D Structures of myocyte enhancer factor 2
Updated on 10-July-2023
1tqe, Transcription and RNA Processing, 3kov – hMEF2A N terminal + DNA – human
3mu6 – hMEF2A N terminal (mutant) + DNA
3p57 – hMEF2A N terminal + DNA + histone acetyltransferase
6c9l – hMEF2B
1n6j – hMEF2B N terminal + DNA + calcineurin-binding protein
1tqe – hMEF2B N terminal + DNA + histone deacylase 9 peptide
6wc5 – hMEF2B + NKX-2.5 + DNA
7x1n – hMEF2D + DNA
5f28 – MEF2C N terminal + focal adhesion kinase 1 - mouse